These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29101421)

  • 1. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT).
    Agrawal L; Azad N; Bahn GD; Ge L; Reaven PD; Hayward RA; Reda DJ; Emanuele NV;
    Diabetologia; 2018 Feb; 61(2):295-299. PubMed ID: 29101421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.
    Abraira C; Duckworth WC; Moritz T;
    Diabetes Obes Metab; 2009 Feb; 11(2):150-6. PubMed ID: 18671796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).
    Pitale SU; Abraira C; Emanuele NV; McCarren M; Henderson WG; Pacold I; Bushnell D; Colwell JA; Nuttall FQ; Levin SR; Sawin CT; Comstock JP; Silbert CK
    Diabetes Care; 2000 Sep; 23(9):1316-20. PubMed ID: 10977025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM).
    Azad N; Emanuele NV; Abraira C; Henderson WG; Colwell J; Levin SR; Nuttall FQ; Comstock JP; Sawin CT; Silbert C; Rubino FA
    J Diabetes Complications; 1999; 13(5-6):307-13. PubMed ID: 10765007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT).
    Azad N; Agrawal L; Emanuele NV; Klein R; Bahn GD; McCarren M; Reaven P; Hayward R; Duckworth W;
    Diabetes Care; 2014 Feb; 37(2):501-6. PubMed ID: 24101699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT).
    Azad N; Agrawal L; Emanuele NV; Klein R; Bahn GD; Reaven P;
    Diabetologia; 2014 Jun; 57(6):1124-31. PubMed ID: 24599110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
    Abraira C; Duckworth W; McCarren M; Emanuele N; Arca D; Reda D; Henderson W;
    J Diabetes Complications; 2003; 17(6):314-22. PubMed ID: 14583175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT).
    Anderson RJ; Bahn GD; Emanuele NV; Marks JB; Duckworth WC;
    Diabetes Care; 2014 Oct; 37(10):2782-8. PubMed ID: 25048382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort.
    Hunt KJ; Jenkins AJ; Fu D; Stevens D; Ma JX; Klein RL; Azar M; Zhang SX; Lopes-Virella MF; Lyons TJ;
    J Diabetes Complications; 2019 Oct; 33(10):107410. PubMed ID: 31434620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).
    Koska J; Saremi A; Bahn G; Yamashita S; Reaven PD;
    Diabetes Care; 2013 Aug; 36(8):2408-14. PubMed ID: 23536583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observation on renal outcomes in the Veterans Affairs Diabetes Trial.
    Agrawal L; Azad N; Emanuele NV; Bahn GD; Kaufman DG; Moritz TE; Duckworth WC; Abraira C;
    Diabetes Care; 2011 Sep; 34(9):2090-4. PubMed ID: 21775749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators.
    Levin SR; Coburn JW; Abraira C; Henderson WG; Colwell JA; Emanuele NV; Nuttall FQ; Sawin CT; Comstock JP; Silbert CK
    Diabetes Care; 2000 Oct; 23(10):1478-85. PubMed ID: 11023140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Blood Glucose Control and Lipids With Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
    Azad N; Bahn GD; Emanuele NV; Agrawal L; Ge L; Reda D; Klein R; Reaven PD; Hayward R;
    Diabetes Care; 2016 May; 39(5):816-22. PubMed ID: 27006510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
    August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.
    Vos FE; Schollum JB; Coulter CV; Manning PJ; Duffull SB; Walker RJ
    Nephrology (Carlton); 2012 Feb; 17(2):182-8. PubMed ID: 21883672
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.